TG-1701
B-Cell Malignancies
Phase 1Early-stage (based on general knowledge)
Key Facts
Indication
B-Cell Malignancies
Phase
Phase 1
Status
Early-stage (based on general knowledge)
Company
About TG Therapeutics
TG Therapeutics is a publicly traded biopharmaceutical company dedicated to advancing innovative therapies for patients with B-cell-mediated diseases. Its primary achievement is the FDA approval and commercialization of BRIUMVI® (ublituximab) for relapsing multiple sclerosis, a significant milestone that has transitioned the company to a commercial entity. The company's strategic direction involves maximizing the commercial potential of BRIUMVI, expanding its label, and advancing its pipeline in oncology and autoimmune indications. TG Therapeutics operates with a focused mission to leverage scientific advances to develop superior treatment options.
View full company profileTherapeutic Areas
Other B-Cell Malignancies Drugs
| Drug | Company | Phase |
|---|---|---|
| Pirtobrutinib | Eli Lilly | Phase 3 |
| Mezagitamab | Kyowa Kirin | Phase 1/2 |
| Velexbru (tirabrutinib) | Ono Pharmaceutical | Phase 3 |
| KT-413 | Kymera Therapeutics | Phase 1 |
| TG-1801 | TG Therapeutics | Phase 1 |
| HMPL-760 | HUTCHMED | Phase 1 |
| REC-3565 | Recursion Pharmaceuticals | Phase 1 |
| UCART20x22 | Cellectis | Phase 1/2 |
| FT819 | Fate Therapeutics | Phase 1 |
| Prulacabtagene leucel (prula-cel, ADI-001) | Adicet Bio | Phase 1 |